Bavencio（Avelumab）

[Brief introduction of Bavencio(Avelumab)]

Bavencio(Avelumab) is a fully human monoclonal antibody (PD-L1 inhibitor) developed by Merck and Pfizer and Lilly. Originally used to treat non-small cell lung cancer (NSCLC).

Bavencio(Avelumab)_ Hong Kong Jimin Pharmaceutical

On March 23, 2017, the US FDA approved Bavencio(Avelumab) for the treatment of adults and pediatric patients with metastatic Meckel’s cell carcinoma (MCC, an aggressive skin cancer) aged 12 and over.

[indications of Bavencio(Avelumab)]

Bavencio(Avelumab) is suitable for the treatment of non-small cell lung cancer (NSCLC) and adult and pediatric patients with metastatic Meckel’s cell cancer (MCC, an aggressive skin cancer) aged 12 years and above.

[Bavencio(Avelumab) specification]

This product is an injection with the specification of 200mg/10mL.

[How to use Bavencio(Avelumab)]

As an intravenous infusion for 60 minutes, 10 mg/kg was given every 2 weeks. When necessary, the first four infusions were given and then [acetaminophen] and an antihistamine were pre-administered.

[Precautions for Bavencio(Avelumab)]

Immune-mediated pneumonia: not for moderate pneumonia; Permanent termination of severe, life-threatening or recurrent moderate pneumonia.

Immune-mediated hepatitis: monitoring changes in liver function. Not for moderate hepatitis; Permanent termination of severe or life-threatening hepatitis.

Immune-mediated colitis: not for moderate or severe colitis; Permanent termination of life-threatening or recurrent severe colitis.

Immune-mediated endocrine diseases: no immune-mediated nephritis and renal insufficiency for serious or life-threatening endocrine diseases;

For moderate or severe nephritis and renal insufficiency; Permanent termination of life-threatening nephritis or renal insufficiency.

Infusion-related reaction: Interrupt or slow down the infusion rate for mild or moderate infusion-related reaction.

Stop infusion and permanently terminate BAVENCIO for serious or life-threatening infusion-related reactions.

Embryo-fetal toxicity: BAVENCIO may cause fetal harm. Suggestions on the potential risks of the fetus and the use of effective contraception.

[Adverse reaction of Bavencio(Avelumab)]

The most common serious adverse reactions of Bavencio(Avelumab) are immune-mediated adverse reactions (pneumonia, hepatitis, colitis, adrenocortical insufficiency, hypotonic and hyperthyroidism, diabetes and nephritis) and life-threatening infusion reactions. Among the 88 patients enrolled in the JAVELINMerkel200 trial, the most common adverse reactions were fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reactions, rash, loss of appetite and peripheral edema. The serious adverse reactions in the trial included acute kidney injury, anemia, abdominal pain, intestinal obstruction, weakness and cellulitis.